Tiapride
| Clinical data | |
|---|---|
| Trade names | Tiapridal | 
| Routes of administration | Oral (tablets), IM, IV | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | ~75% (oral) (Tmax = 1 hour) | 
| Protein binding | Negligible | 
| Elimination half-life | 2.9–3.6 hours | 
| Excretion | Urine (70% as unchanged tiapride) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.717 | 
| Chemical and physical data | |
| Formula | C15H24N2O4S | 
| Molar mass | 328.43 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| (verify) | |
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.